

Atrial Fibrillation Pipeline Review – Analysis Of Key Players And Enlists All Their Major And Minor Projects 2016

PUNE, INDIA, September 12, 2016 /EINPresswire.com/ -- <u>Atrial Fibrillation - Pipeline</u> <u>Review, H2 2016</u>

COMPLETE REPORT DETAILS @ https://www.wiseguyreports.com/reports/636747atrial-fibrillation-pipeline-review-h2-2016

The, 'Atrial Fibrillation - Pipeline Review, H2 2016', provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.



For more information or any query mail at sales@wiseguyreports.com

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data.

GET A SAMPLE REPORT @ <u>https://www.wiseguyreports.com/sample-request/636747-atrial-fibrillation-pipeline-review-h2-2016</u> Scope

- The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation

- The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects

- The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents – Major Key Points

Atrial Fibrillation - Companies Involved in Therapeutics Development 20 ARCA biopharma, Inc. 20 AstraZeneca PIc 21 Bristol-Myers Squibb Company 22 Cardiome Pharma Corp. 23 Daiichi Sankyo Company, Limited 24 Dong-A Socio Holdings Co. Ltd. 25 Gilead Sciences, Inc. 26 Laboratoires Pierre Fabre SA 27 Nissan Chemical Industries, Ltd. 28 OMEICOS Therapeutics GmbH 29 Otsuka Holdings Co., Ltd. 30 Xention Limited 31 Atrial Fibrillation - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39

Continue.....

For more information or any query mail at sales@wiseguyreports.com

GET EXCLUSIVE DISCOUNT ON THIS REPORT @ <u>https://www.wiseguyreports.com/check-discount/636747-atrial-fibrillation-pipeline-review-h2-2016</u>

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and subcategories.

Norah Trent WiseGuy Research Consultants Pvt. Ltd. 16468459349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.